Opendata, web and dolomites

BREAK SIGNED

Blue light remote analgesia with K+ channels

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 BREAK project word cloud

Explore the words cloud of the BREAK project. It provides you a very rough idea of what is the project "BREAK" about.

designed    rats    reporting    disorder    worse    device    progress    network    actually    class    injected    blue    lamp    area    neuron    20    mostly    12    optical    stakeholder    constitute    silencing    nervous    painful    originally    nonspecific    centers    version    treat    global    pain    treatments    nausea    fruitful    patients    drugs    leveraging    entities    invasiveness    genes    damage    adults    peripheral    hard    opioids    abnormal    restraining    kept    brain    break    virus    leads    spectrum    synergy    situation    blink2    treatment    academic    genetically    relief    pharma    cells    proteins    distance    despite    inhibitory    causing    companies    thirds    minutes    solution    stimuli    optogenetic    population    extremely    difficult    chronic    interpret    medical    demonstrated    tool    diagnose    implant    commercial    explore    origin    lower    adoption    normally    trauma    partial    engineered    central    gt    cm    np    initiated    weeks    plan    characterised    hours    vivo    illness    first    hospitals    antidepressants    cp    protein    addiction    drug    light    exact    skin    investor    prolonged    invasive       neuropathic    experiments   

Project "BREAK" data sheet

The following table provides information about the project.

Coordinator
UNIVERSITA DEGLI STUDI DI MILANO 

Organization address
address: Via Festa Del Perdono 7
city: MILANO
postcode: 20122
website: www.unimi.it

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Italy [IT]
 Total cost 0 €
 EC max contribution 150˙000 € (0%)
 Programme 1. H2020-EU.1.1. (EXCELLENT SCIENCE - European Research Council (ERC))
 Code Call ERC-2019-PoC
 Funding Scheme ERC-POC-LS
 Starting year 2019
 Duration (year-month-day) from 2019-12-01   to  2021-05-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    UNIVERSITA DEGLI STUDI DI MILANO IT (MILANO) coordinator 150˙000.00

Map

 Project objective

Chronic pain (CP) is a medical condition affecting around 20% of adults in Europe, characterised by an abnormal duration of pain (> 12 weeks) originally initiated by a trauma or illness. Despite significant progress, CP remains extremely hard to treat, with only one-third to two-thirds of patients reporting adequate some pain relief. This situation is even worse for neuropathic pain (NP), a specific class of CP affecting 8% of global population and whose origin mostly depend on peripheral or central nervous damage or disorder, which leads the brain to interpret as pain normally non painful stimuli. NP is difficult to treat due to the large number of entities involved (cells, genes and proteins working in synergy), which makes it hard to rapidly diagnose the exact cause of pain. Drugs targeting the central nervous system (e.g. antidepressants and opioids) provide only partial pain relief and are nonspecific, also causing side effects like addiction, and nausea, thus restraining their adoption for prolonged treatments. BREAK is the first non-invasive inhibitory optogenetic tool specifically designed for NP treatment, with potential application to the whole spectrum of CP. BREAK is composed of a drug and an optical device. The protein BLINK2 is injected in the painful area using a genetically engineered virus, and respond to a specific blue light by silencing the addressed neuron. The lamp can be kept at some distance (cm) from the skin and no implant is required. Just some minutes of treatment results in hours of pain relief, making the invasiveness of BREAK far lower than actually existing solution. A first version of BREAK has already demonstrated in in-vivo experiments on rats. During this project we plan to further develop the treatment and explore its commercial potential. In particular, leveraging from the experience of different partners, we will constitute a fruitful stakeholder network, including Academic centers, hospitals, pharma companies and investor

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "BREAK" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "BREAK" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.1.1.)

PP-MAGIC (2020)

(Photo-)Control of Persisters: Targeting the Magic Spot

Read More  

INTERACT (2019)

Phylogenetic association mapping and its application to secondary metabolite variation in Brassicaceae species

Read More  

CERQUTE (2020)

Certification of quantum technologies

Read More  
lastchecktime (2021-11-28 20:59:51) correctly updated